{"id":"candesartan-cilexetil-amlodipine-besylate","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia (with ARB component)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan cilexetil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine besylate is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, these complementary mechanisms provide additive blood pressure reduction.","oneSentence":"This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:41.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (high blood pressure)"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT07064525","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-12-05","conditions":"Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure","enrollment":252},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT06646354","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia","status":"ENROLLING_BY_INVITATION","sponsor":"Hyundai Pharm","startDate":"2025-04-22","conditions":"Hypertension, Primary Hypercholesterolaemia","enrollment":125},{"nctId":"NCT01806311","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2012-12","conditions":"Hypertension","enrollment":36},{"nctId":"NCT02988362","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)","status":"COMPLETED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2016-12-14","conditions":"Hypertension","enrollment":42},{"nctId":"NCT06826872","phase":"PHASE2","title":"Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-06-12","conditions":"Hypertension, Essential, Cardiovascular Diseases, Cardiology","enrollment":252},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":"Hypertension","enrollment":62},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT06460896","phase":"NA","title":"Analysis of the Influence of Gastric By-Pass on the Pharmacokinetics of Common Drugs","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09","conditions":"Bypass Bariatric Surgery","enrollment":64},{"nctId":"NCT06212648","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-03-25","conditions":"Hypertension, Essential Hypertension","enrollment":253},{"nctId":"NCT02368652","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-12","conditions":"Essential Hypertension","enrollment":181},{"nctId":"NCT02368665","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-12","conditions":"Essential Hypertension","enrollment":180},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT03847506","phase":"PHASE4","title":"Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2018-07-05","conditions":"Hypertension, Hyperlipidemia","enrollment":127},{"nctId":"NCT05169021","phase":"PHASE4","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-12-31","conditions":"Cerebral Small Vessel Diseases, Stroke","enrollment":15000},{"nctId":"NCT02774460","phase":"PHASE4","title":"The Precision Hypertension Care Study","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2017-02-20","conditions":"Hypertension","enrollment":280},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01984164","phase":"PHASE2","title":"CAndesartan vs LIsinopril Effects on the BRain","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-08-20","conditions":"Hypertension, Mild Cognitive Impairment","enrollment":176},{"nctId":"NCT02651870","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-04-22","conditions":"Hypertension","enrollment":135},{"nctId":"NCT04521023","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-09-20","conditions":"Hypertension","enrollment":132},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT04245046","phase":"PHASE1","title":"Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin","status":"COMPLETED","sponsor":"Midas Pharma GmbH","startDate":"2019-01-18","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT03231982","phase":"PHASE4","title":"Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2017-04-17","conditions":"Hypertension","enrollment":210},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT02068495","phase":"","title":"Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance \"Hypertension: Long-Term Use\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-06-15","conditions":"Hypertension","enrollment":3409},{"nctId":"NCT02969265","phase":"PHASE3","title":"An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2017-05-09","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01611077","phase":"PHASE4","title":"Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2012-01","conditions":"Hypertension","enrollment":88},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02944734","phase":"PHASE2","title":"Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2014-09","conditions":"Essential Hypertension","enrollment":392},{"nctId":"NCT00360178","phase":"PHASE3","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Hypertension","enrollment":198},{"nctId":"NCT02811731","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-04","conditions":"Hypertension","enrollment":32},{"nctId":"NCT02801526","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-04","conditions":"Hypertension","enrollment":32},{"nctId":"NCT01613209","phase":"PHASE3","title":"Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2011-12","conditions":"Hypertension","enrollment":83},{"nctId":"NCT02548286","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-08","conditions":"Hypertension","enrollment":53},{"nctId":"NCT02206165","phase":"PHASE2","title":"A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-03","conditions":"Essential Hypertension","enrollment":456},{"nctId":"NCT02186496","phase":"PHASE1","title":"Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-07","conditions":"Hypertension","enrollment":32},{"nctId":"NCT02064621","phase":"PHASE1","title":"CKD-330 Drug-Drug Interaction Study (Candesartan)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-06","conditions":"Hypertension","enrollment":24},{"nctId":"NCT02064556","phase":"PHASE1","title":"CKD-330 Drug-Drug Interaction Study (Amlodipine)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-05","conditions":"Hypertension","enrollment":24},{"nctId":"NCT02173912","phase":"PHASE1","title":"Bioequivalence Study of CJ-30059","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2014-06","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT02059616","phase":"PHASE2","title":"A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2014-02","conditions":"Essential Hypertension","enrollment":384},{"nctId":"NCT01926652","phase":"PHASE1","title":"Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2013-07","conditions":"Healthy","enrollment":34},{"nctId":"NCT00538486","phase":"PHASE4","title":"A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2008-02","conditions":"Hypertension, Obesity","enrollment":360},{"nctId":"NCT01845272","phase":"PHASE1","title":"Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2013-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00125463","phase":"PHASE3","title":"Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients","status":"UNKNOWN","sponsor":"The Japanese Society of Hypertension","startDate":"2001-09","conditions":"Hypertension, Cardiovascular Diseases","enrollment":3200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg"],"phase":"marketed","status":"active","brandName":"Candesartan cilexetil/Amlodipine besylate","genericName":"Candesartan cilexetil/Amlodipine besylate","companyName":"HK inno.N Corporation","companyId":"hk-inno-n-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance. Used for Hypertension (high blood pressure).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}